Technology company Tempus has introduced new testing solutions to help identify patients with HER2 or FOLR1-expressing tumours.
The new HER2 and FOLR1 testing solutions will help identify patients eligible for targeted therapies such as antibody-drug conjugates (ADCs).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Tempus said the HER2 and FOLR1 testing by immunohistochemistry (IHC), as an add-on to the company’s xT or xR next-generation sequencing assays, is made available for all solid tumour cancers.
The two IHC tests are recommended in clinical guidelines for several types of cancers. It can also be ordered for other cancer types at the clinician’s discretion.
Tempus noted that FOLR1 testing is recommended for patients, who have epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Tempus oncology chief medical officer Ezra Cohen said: “Expanding our offerings to include tests for specific, predictive biomarkers, like HER2, can help reveal a patient’s responsiveness to therapies that have the potential to positively impact their outcome.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“These are the kind of critical tools that we are arming physicians with as new, targeted therapies are made available for patients.”
In a separate announcement, Tempu and AstraZeneca have expanded their partnership, utilising Tempus Next to provide doctors with technology that facilitates the administration of guideline-directed biomarker testing for patients suffering from non-small cell lung cancer (NSCLC).
The two companies are currently building on a pilot programme that uses Next, Tempus’ care pathway intelligence platform, to help doctors decide whether to recommend guideline-directed molecular testing for patients with NSCLC, which includes testing for epidermal growth factor receptor (EGFR) mutations.
Additionally, Tempus has announced the clinical launch of its minimal residual disease test portfolio – the Tempus xM test and the xM (NeXT Personal Dx) test by Personalis.
This portfolio comprises both a tumour-naïve assay and a tumour-informed assay, which can identify residual disease or early cancer recurrence and monitor immunotherapy treatment response.
These tests provide valuable insights to inform patient management strategies.
